Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 21471435)

1.

Alzheimer's disease: the challenge of the second century.

Holtzman DM, Morris JC, Goate AM.

Sci Transl Med. 2011 Apr 6;3(77):77sr1. doi: 10.1126/scitranslmed.3002369. Review.

2.

Understanding the cause of sporadic Alzheimer's disease.

Zetterberg H, Mattsson N.

Expert Rev Neurother. 2014 Jun;14(6):621-30. doi: 10.1586/14737175.2014.915740. Review.

PMID:
24852227
3.

Synapses and Alzheimer's disease.

Sheng M, Sabatini BL, Südhof TC.

Cold Spring Harb Perspect Biol. 2012 May 1;4(5). pii: a005777. doi: 10.1101/cshperspect.a005777. Review.

4.

Novel disease-modifying therapies for Alzheimer's disease.

Jiang T, Yu JT, Tan L.

J Alzheimers Dis. 2012;31(3):475-92. doi: 10.3233/JAD-2012-120640. Review.

PMID:
22669013
5.

The study of Golgi apparatus in Alzheimer's disease.

Hu Z, Zeng L, Huang Z, Zhang J, Li T.

Neurochem Res. 2007 Aug;32(8):1265-77. Epub 2007 Mar 31. Review.

PMID:
17401657
6.

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.

Perrin RJ, Fagan AM, Holtzman DM.

Nature. 2009 Oct 15;461(7266):916-22. doi: 10.1038/nature08538. Review.

7.

Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.

Bateman RJ, Klunk WE.

Neurotherapeutics. 2008 Jul;5(3):381-90. doi: 10.1016/j.nurt.2008.05.009. Review.

8.
9.

A century of Alzheimer's disease.

Goedert M, Spillantini MG.

Science. 2006 Nov 3;314(5800):777-81. Review.

PMID:
17082447
10.

Targeting Abeta and tau in Alzheimer's disease, an early interim report.

Golde TE, Petrucelli L, Lewis J.

Exp Neurol. 2010 Jun;223(2):252-66. doi: 10.1016/j.expneurol.2009.07.035. Epub 2009 Aug 27. Review.

11.

Genetic markers for diagnosis and pathogenesis of Alzheimer's disease.

Kim DH, Yeo SH, Park JM, Choi JY, Lee TH, Park SY, Ock MS, Eo J, Kim HS, Cha HJ.

Gene. 2014 Jul 25;545(2):185-93. doi: 10.1016/j.gene.2014.05.031. Epub 2014 May 15. Review.

PMID:
24838203
12.

Progress in the development of new drugs in Alzheimer's disease.

Piau A, Nourhashémi F, Hein C, Caillaud C, Vellas B.

J Nutr Health Aging. 2011 Jan;15(1):45-57.

PMID:
21267520
13.

Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid-β cascade.

Belkacemi A, Ramassamy C.

Free Radic Biol Med. 2012 Feb 1;52(3):593-600. doi: 10.1016/j.freeradbiomed.2011.11.020. Epub 2011 Dec 8. Review.

PMID:
22172527
14.

Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction.

van Norden AG, van Dijk EJ, de Laat KF, Scheltens P, Olderikkert MG, de Leeuw FE.

Biochim Biophys Acta. 2012 Mar;1822(3):340-9. doi: 10.1016/j.bbadis.2011.07.003. Epub 2011 Jul 14.

15.

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.

Ittner LM, Götz J.

Nat Rev Neurosci. 2011 Feb;12(2):65-72. doi: 10.1038/nrn2967. Epub 2010 Dec 31. Review.

PMID:
21193853
16.

Future targeted disease modifying drugs for Alzheimer's disease.

Dash SK.

Recent Pat CNS Drug Discov. 2011 Jan;6(1):65-76. Review.

PMID:
21073430
18.

Does Alzheimer's disease begin in the brainstem?

Simic G, Stanic G, Mladinov M, Jovanov-Milosevic N, Kostovic I, Hof PR.

Neuropathol Appl Neurobiol. 2009 Dec;35(6):532-54. doi: 10.1111/j.1365-2990.2009.01038.x. Epub 2009 Aug 4.

19.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
20.

Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.

Prvulovic D, Hampel H.

Clin Chem Lab Med. 2011 Mar;49(3):367-74. doi: 10.1515/CCLM.2011.087. Epub 2011 Feb 23. Review.

PMID:
21342022
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk